(BIVI) – Why BioVie (BIVI) Shares Are Trading Higher Premarket Today

  • BioVie Inc BIVI announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). 
  • The company says that NE3107 is pursuing a two-pronged approach targeting neuroinflammation and insulin resistance.
  • The trial enrolled a total of 23 patients. Initial results showed that the measurements for most patients improved with NE3107 treatment, although MCI/mild AD patients showed greater change.
  • A large proportion of MCI/mild AD patients in the trial showed improvements with NE3107 compared to baseline as scored by the clinician (94% of 17 patients improved), the study partner (65% of 17 patients improved), and the patient (88% of 17 patients improved).
  • NE3107 is associated with significant improvements in cognition, as evidenced by the ADAS-Cog12 scale. 82% of 17 patients experienced a 2.6-point decrease in ADAS-Cog12.
  • 62% of 13 MCI/mild AD patients had decreased plasma TNF with a mean change of -0.55 pg/mL.
  • Early analyses of imaging data suggest fundamental biological improvements in blood flow and reduced oxidative stress.
  • No drug-related adverse events were reported.
  • Price Action: BIVI shares are up 36.60% at $4.70 during the premarket session on the last check Wednesday.

Image and article originally from www.benzinga.com. Read the original article here.